Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2023

(Commission File No. 001-40241)

---

LAVA Therapeutics N.V.

(Translation of registrant’s name into English)

---

Yalelaan 60

3584 CM Utrecht, The Netherlands

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒ Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes  ☐    No  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes  ☐    No  ☐

​

​

​

​

---

LAVA Therapeutics, N.V.

Effective February 6, 2023, LAVA Therapeutics, N.V. appointed Dr. Charles Morris as chief medical officer, replacing Benjamin Winograd, MD, Ph.D.

On February 6, 2023, the Company issued a press release related to the foregoing matters. A copy of this press release is filed herewith as Exhibit 99.1

​

EXHIBIT LIST

Exhibit		Description
99.1	​	Press Release, dated February 6, 2023

​

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

​	​	​
​	LAVA Therapeutics, N.V.
​	(Registrant)
​	​	​
Date: February 6, 2023	By:	/s/ Fred Powell
​	Fred Powell
​	Chief Financial Officer

​

---